STK3 KO cell lysate available now. KO validated by Western blot. Free of charge wild type control included. Knockout achieved by using CRISPR/Cas9, 1 bp insertion in exon2.
0610042I06Rik, EC 2.7.11.1, FLJ90748, KB 1458E12.1, KRS1, Kinase responsive to stress 1, MST-2, MST-3, Mammalian STE20-like protein kinase 2, Mammalian sterile 20-like 2, Mess1, STE20-like kinase MST2, STK3_HUMAN, Serine/threonine kinase 3, Serine/threonine kinase 3 (STE20 homolog, yeast), Serine/threonine kinase 3 (Ste20, yeast homolog), Serine/threonine-protein kinase 3, Serine/threonine-protein kinase Krs-1, wu:fc19e11, zgc:55383
STK3 KO cell lysate available now. KO validated by Western blot. Free of charge wild type control included. Knockout achieved by using CRISPR/Cas9, 1 bp insertion in exon2.
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.
Lysate preparation: Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10). This means that the protein of interest is denatured. If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.
User storage instructions: Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.
This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our limited use license and patent pages.
STK3 also known as MST-2 is a serine/threonine protein kinase with a molecular mass of around 60 kDa. It plays an integral role in cell signaling by phosphorylating and activating downstream targets. MST-2 localizes mainly in the cytoplasm and is expressed broadly across various tissues with notable activity in liver kidney and heart tissues. This kinase contributes to the regulation of cell shape and apoptosis reinforcing its importance in cellular homeostasis.
STK3/MST-2 is a core component of the Hippo signaling pathway which controls organ size by regulating cell proliferation and apoptosis. MST-2 often interacts with other proteins and participates in functional complexes notably with MOB1 and LATS1/2. These interactions are essential for transmitting growth inhibitory signals. Through its kinase activity MST-2 phosphorylates and activates these molecules initiating a cascade that ultimately influences gene expression impacting cell cycle and cell death processes.
MST-2 plays a pivotal role not only in the Hippo pathway but also in the MAPK signaling network. In the Hippo pathway MST-2 phosphorylates components like LATS1/2 subsequently affecting the translocation and activity of YAP/TAZ transcription factors which control cell proliferation and survival. In the MAPK pathway MST-2 can interact with other kinases such as ASK1 to influence stress response signaling. These interactions demonstrate how MST-2 integrates signals between pathways to mediate critical decisions in cell life and death.
MST-2 has implications in cancer and cardiac diseases. Dysregulation of the Hippo pathway involving MST-2 is frequently observed in various cancers where impaired MST-2 function contributes to unchecked cell growth and tumor progression. Moreover MST-2 connects with other proteins like YAP often overactive in cancers emphasizing its role in controlling cell division. In cardiac context alterations in MST-2 activity relate to cardiac hypertrophy as proper functioning of the kinase is necessary to maintain cardiac tissue architecture and response to stress.
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
Lane 1: Wild-type HeLa cell lysate (20µg)
Lane 2: STK3 knockout HeLa cell lysate (20µg)
Lanes 1- 2: Merged signal (red and green). Green - Anti-STK3/MST-2 antibody [3067C3a] ab71960 observed at 56 kDa. Red - loading control, Anti-GAPDH antibody [EPR16891] - Loading Control ab181602 observed at 37 kDa.
Anti-STK3/MST-2 antibody [3067C3a] ab71960 Anti-STK3/MST-2 antibody [3067C3a] was shown to specifically react with STK3/MST-2 in wild-type HeLa cells in western blot. Loss of signal was observed when knockout cell line Human STK3 (MST-2) knockout HeLa cell line ab265082 (knockout cell lysate ab257714) was used. Wild-type and STK3/MST-2 knockout samples were subjected to SDS-PAGE. Anti-STK3/MST-2 antibody [3067C3a] ab71960 and Anti-GAPDH antibody[EPR16891] - Loading Control (Anti-GAPDH antibody [EPR16891] - Loading Control ab181602) were incubated overnight at 4°C at 1 in 10000 and 1 in 20000 dilution respectively. Blots were developed with Goat anti-Mouse IgG H&L (IRDye® 800CW) preadsorbed (Goat anti-Mouse IgG H&L (IRDye® 800CW) preadsorbed ab216772) and Goat Anti-Rabbit IgG H&L (IRDye® 680RD) preadsorbed (Goat Anti-Rabbit IgG H&L (IRDye® 680RD) preadsorbed ab216777) secondary antibodies at 1 in 20000 dilution for 1 hour at room temperature before imaging.
All lanes: Western blot - Anti-STK3/MST-2 antibody [3067C3a] (Anti-STK3/MST-2 antibody [3067C3a] ab71960) at 1/10000 dilution
Lane 1: Wild-type HeLa cell lysate at 20 µg
Lane 2: STK3 knockout HeLa cell lysate at 20 µg
Lane 2: Western blot - Human STK3 (MST-2) knockout HeLa cell line (Human STK3 (MST-2) knockout HeLa cell line ab265082)
Performed under reducing conditions.
Predicted band size: 56 kDa
Observed band size: 56 kDa
Homozygous: 1 bp insertion in exon2
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com